
4 Ways to Keep Your Joints Healthy
But I've gotten some relief by stretching for five minutes each morning. I picked this tip up from Dr. Gbolahan Okubadejo, a spine surgeon in New York and New Jersey. He told me that he's been doing this every morning to keep his joints and muscles limber. Now I do the same.
We should think of our joints as more than just 'hinges on a machine,' said Dr. M. Lucius Pomerantz, an orthopedic surgeon in San Diego. 'We should be nurturing them,' he said. A joint is anywhere two bones meet, and we have about 350 of them. They're essential for movement, flexibility and stability.
I asked experts for their best tips on how to keep them supple.
Regular movement are critical for joint health, Dr. Okubadejo said. Our hip, shoulder, knee and elbow joints are called synovial joints; they contain fluid that helps nourish the cartilage by preventing wear while the joint is in motion.
Movement helps circulate the fluid and lubricate those joints, averting stiffness and discomfort, said Dean Padavan, associate program director of Primary Care Sports Medicine Fellowship at Atlantic Health.
In addition to regular stretching, Dr. Okubadejo recommends 150 minutes a week of moderate to vigorous exercise. That could be gentler, joint-friendly activities such as yoga, Pilates and Tai Chi, or something more intense, like swimming laps.
Want all of The Times? Subscribe.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Aptose Reports Second Quarter 2025 Results
Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at 120 mg Dose Cohort Safety Review Committee (CSRC) Recommends Tuspetinib Dose Escalation to 160 mg Dose Hanmi Continues to Support Development of Tuspetinib SAN DIEGO and TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ('Aptose' or the 'Company') (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the second quarter ended June 30, 2025, and provided a corporate update. 'During the second quarter, the TUSCANY triplet trial continued to progress well. Our investigators are eager to improve outcomes for patients with mutations that are especially difficult to treat in AML, and we continue to observe exciting safety and activity with the addition of TUS to the VEN+AZA standard treatment,' said William G. Rice, Ph.D., Chairman, President and Chief Executive Officer of Aptose. 'We look forward to providing updates to the data we presented at EHA in June.' Key Corporate Highlights Tuspetinib Data Reported at the European Hematology Association (EHA) 2025 Congress in Oral Presentation – Tuspetinib based TUS+VEN+AZA triplet therapy is being advanced in the TUSCANY Phase 1/2 trial with the goal of creating a one-of-a-kind frontline therapy for newly diagnosed AML patients that is safe and active across diverse AML populations (mutation agnostic triplet frontline therapy), including patients without FLT3 mutations (wildtype FLT3). Data from the first two cohorts, with a 40 mg or 80 mg dose of tuspetinib in the TUS+VEN+AZA combination, reveal promising clinical safety and antileukemic activity and were presented in an oral presentation at EHA 2025 in June (press release here) by Dr. Gabriel Mannis, Associate Professor of Medicine, Stanford University School of Medicine, and an investigator in the TUSCANY study. Dr. Mannis also noted three patients were rapidly enrolled on the third dose cohort of 120 mg TUS in the TUS+VEN+AZA triplet, and that no DLTs were observed. Among the key findings: Multiple CRs were achieved, at the initial dose of 40 mg (3 of 4 CRs and minimal residual disease (MRD)-negative) and at the 80 mg dose (3 of 3 CR/CRi). Regardless of FLT3, TP53, NPM1, or myelodysplasia related mutation status, TUS demonstrated activity in newly diagnosed AML patients. MRD-negative responses were achieved across diverse genetic populations, including in subjects with biallelic TP53 mutations and complex karyotypes. In addition, TUS can be administered safely with standard-of-care dosing of VEN/AZA, and TUS PK properties are not significantly altered by VEN, AZA, antifungals or food. No prolonged myelosuppression was noted in Cycle 1 in the absence of AML and there were no treatment-related deaths with 9 out of 10 enrolled subjects remaining on study treatment. TUS Continues to Demonstrate Safety and CRs at 120 mg Dose in the TUSCANY Triplet Trial; 160 mg Dose Cohort Now Open After Dose Escalation Decision by CSRC – The fourth dosing cohort of 160 mg of TUS in the TUS+VEN+AZA TUSCANY trial is now open for enrollment after the CSRC reviewed the current data from the 120 mg TUS dose cohort. All patients treated in the 120 mg dose cohort remain on study while enrollment is open for the 160 mg dose cohort. Aptose Clinical Data Accepted for Poster Presentation at European School of Haematology (ESH) 7th International Conference – Aptose recently was notified that its abstract 'TUSCANY Study of Safety and Efficacy of Tuspetinib plus Standard of Care Venetoclax and Azacitidine in Study Participants with Newly Diagnosed AML Ineligible for Induction Chemotherapy' was accepted for a poster presentation at the ESH 7th International Conference on Acute Myeloid Leukemia 'Molecular and Translational': Advances in Biology and Treatment, being held October 16-18, 2025 in Estoril, Portugal. Aptose and Hanmi Enter Loan Agreement to Advance Development of Tuspetinib in Triplet Therapy for AML – During the quarter, Aptose announced that it entered into a loan agreement with Hanmi Pharmaceutical Co. Ltd. ('Hanmi'). The Loan Agreement is an uncommitted facility for up to US$8.5million, administered through multiple advances for the purpose of continued clinical development of TUS (press release here). To date, Aptose has received an aggregate of US$5.6M under the Loan Agreement. Aptose Trading on OTCQB Market – On July 1st, Aptose announced that it had been upgraded to list for trading on the OTCQB Market under the ticker symbol 'APTOF,' in addition to the Company's continued listing on the Toronto Stock Exchange (TSX) under the symbol 'APS.' The OTCQB Market is for early stage and developing U.S. and international companies. Companies listed on the OTCQB Market are current in their reporting and undergo an annual verification and management certification process. Investors can find Real-Time quotes and market information for the company on Aptose Selects Ernst & Young as its New Independent Auditor and will Hold a Reconvened Meeting of its Shareholders on August 22, 2025 – Earlier this month, Aptose announced that its Board of Directors unanimously approved the selection of Ernst & Young LLP ('EY') as the Company's independent registered public accounting firm to serve as the Company's independent auditor. The Company had adjourned its Annual and Special Meeting of shareholders held on May 27, 2025 (the 'Meeting'), for the purposes of completing its search for a successor independent auditor, and will reconvene the Meeting of shareholders on August 22, 2025 at 10:00 a.m. (Eastern Time) (the'Reconvened Meeting') to vote on the appointment of EY. Shareholders are invited to attend the Reconvened Meeting by using the live webcast link here: Only registered shareholders and duly appointed proxyholders as of the record date on April 22, 2025, will be entitled to vote and ask questions at the Reconvened Meeting. Completed and Planned Value-Creating Milestones 2025: 1H Reported safety and efficacy with 40mg TUS+VEN+AZA Reported safety and efficacy with 80mg TUS+VEN+AZA 2025: European Hematology Association (EHA) Report maturing data from TUS+VEN+AZA triplet study 2025: 2H Reported safety and efficacy with 120 mg TUS+VEN+AZA CSRC review of data; decision to dose escalate to 160 mg TUS+VEN+AZA Report evolving data from 120 mg TUS+VEN+AZA triplet 2025: American Society of Hematology (ASH) Report response rate and durability of TUS+VEN+AZA triplet Select TUS dose for TUS+VEN+HMA triplet Ph 2/3 PIVOTAL trials Prepare for initiation of Ph 2/3 PIVOTAL program FINANCIAL RESULTS OF OPERATIONSAptose Biosciences of Operations Data(unaudited)($ in thousands, except for share and per share data) Three months endedJune 30, Six months endedJune 30, 2025 2024 2025 2024 Expenses: Research and development $ 3,298 $ 4,413 $ 5,662 $ 10,858 General and administrative 3,623 2,932 6,720 6,247 Operating expenses 6,921 7,345 12,382 17,105 Other (loss) income, net (122 ) 93 (204 ) 213 Net loss $ (7,043 ) $ (7,252 ) $ (12,586 ) $ (16,892 ) Net loss per share, basic and diluted $ (2.76 ) $ (12.99 ) $ (5.38 ) $ (33.91 ) Weighted average number of common shares outstanding used in the calculation of basic and diluted loss per common share 2,552,429 558,476 2,340,535 498,113 Net loss for the quarter ended June 30, 2025 decreased by $0.2 million to $7.0 million, as compared to $7.3 million for the comparable period in 2024. Net loss for the six months ended June 30, 2025 decreased by $4.3 million to $12.6 million, as compared to $16.9 million for the comparable period in 2024. Aptose Biosciences Sheet Data(unaudited)($ in thousands) June 30, December 31, 2025 2024 Cash, cash equivalents and restricted cash equivalents $ 1,298 $ 6,707 Working capital (5,729 ) 5,053 Total assets 5,591 10,127 Long-term liabilities 10,962 10,193 Accumulated deficit (553,553 ) (540,967 ) Shareholders' deficit (14,371 ) (4,543 ) Total cash, cash equivalents and restricted cash equivalents as of June 30, 2025 were $1.3 million. The Company does not have sufficient cash to fund operations and relies on advances made by Hanmi to fund operations. The Company is actively deploying financing and cost reduction efforts to extend cash runway. As of August 8, 2025, we had 2,552,429 common shares of the Company ('Common Shares') issued and outstanding. In addition, there were 38,211 Common Shares issuable upon the exercise of outstanding stock options and there were 1,267,585 Common Shares issuable upon the exercise of the outstanding warrants. RESEARCH AND DEVELOPMENT EXPENSES Research and development expenses for the three and six months ended June 30, 2025 and 2024 were as follows: Three months ended Six months ended June 30, June 30, (in thousands) 2025 2024 2025 2024 Program costs – Tuspetinib $ 2,233 $ 2,666 $ 3,712 $ 6,589 Program costs – Luxeptinib 100 304 198 512 Program costs – APTO-253 - (9 ) - 13 Personnel related expenses 952 1,379 1,598 3,333 Stock-based compensation 13 70 154 398 Depreciation of equipment - 3 - 13 Total $ 3,298 $ 4,413 $ 5,662 $ 10,858 Research and development expenses decreased by $1.1 million to $3.3 million for the quarter ended June 30, 2025, as compared to $4.4 million for the comparable period in 2024. Changes to the components of our research and development expenses presented in the table above are primarily as a result of the following events: Program costs for tuspetinib were $2.2 million for the quarter ended June 30, 2025, compared with $2.7 million for the comparable period in 2024. The lower program costs for tuspetinib in the current period are attributable to reduced activity in our APTIVATE clinical trial, reduced manufacturing activity, and related expenses. Program costs for luxeptinib decreased by approximately $0.2 million primarily due to lower clinical trial and manufacturing activities. The Company discontinued further development of APTO-253. Personnel-related expenses decreased by $0.4 million due to lower headcount for research and development personnel in the current quarter. Stock-based compensation decreased by $57,000 in the quarter ended June 30, 2025, compared to the comparable period in 2024, primarily due to stock options forfeited and/or vested in prior periods that are no longer being expensed resulting in lower expense in the current period. Research and development expenses decreased by $5.2 million to $5.7 million for the six months ended June 30, 2025, as compared to $10.9 million for the comparable period in 2024. Changes to the components of our research and development expenses presented in the table above are primarily as a result of the following events: Program costs for tuspetinib were $3.7 million for the six months ending June 30, 2025, compared to $6.6 million for the comparable period in 2024. The increased costs associated with the TUSCANY study were offset by a decrease in tuspetinib development expenses during the current period. This reduction is due to the conclusion of activities in our APTIVATE clinical trial during the current period, compared to higher APTIVATE activities during the six months ended June 30, 2024, as well as lower manufacturing and related development costs. Program costs for luxeptinib decreased by approximately $0.3 million primarily due to lower clinical trial and manufacturing activities. The Company discontinued further development of APTO-253. Personnel-related expenses decreased by $1.7 million due to lower headcount for research and development personnel in the current quarter. Stock-based compensation decreased by approximately $0.2 million in the six months ended June 30, 2025, compared to the comparable period in 2024, primarily due to stock options forfeited and/or vested in prior periods that are no longer being expensed resulting in lower expense in the current period. About Aptose Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company's lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Canadian and U.S. securities laws, including, but not limited to, statements regarding the Company's clinical development plans, the clinical potential, anti-cancer activity, therapeutic potential and applications and safety profile of tuspetinib, clinical trials, upcoming milestones, financing and cost reduction efforts, expectations regarding capital available to the Company to fund planned Company operations, the Company's cash runway, and statements relating to the Company's plans, objectives, expectations and intentions and other statements including words such as 'continue', 'expect', 'intend', 'will', 'hope' 'should', 'would', 'may', 'potential' and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us, are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance or achievements to be materially different from any future results, performance or achievements described in this press release. Such factors could include, among others: our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market and economic conditions; unexpected manufacturing defects, the evolving regulatory and political landscape and the funding of government programs and other risks detailed from time-to-time in our ongoing current reports, quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein. For further information, please contact: Aptose Biosciences PietropaoloCorporate Communications & Investor Relations201-923-2049spietropaolo@ in to access your portfolio
Yahoo
18 minutes ago
- Yahoo
Provident Healthcare Partners Advises OrthoNY on its Partnership with Zenyth Partners
BOSTON and NEW YORK, Aug. 13, 2025 /PRNewswire/ -- Provident Healthcare Partners ("Provident"), a leading healthcare investment banking firm, announced it has advised OrthoNY in a recapitalization with Zenyth Partners ("Zenyth") to form Evolve Orthopedic Partners ("Evolve"). OrthoNY is a leading orthopedic care provider in the Capital Region of New York with 43 physicians and 84 total providers, dedicated to providing high quality musculoskeletal care to patients across its eight clinics and three ambulatory surgery centers. Provident's deal team was led by Managing Directors Eric Major and Scott Davis. McGuireWoods LLP served as legal counsel to ONY, and Alston & Bird LLP served as legal counsel to Zenyth. "Provident brought the clarity, confidence and expertise we needed to navigate this complex process. From day one, they took the time to understand our goals, challenge our thinking and keep us focused on the bigger picture," said David Fitzgerald, CEO of OrthoNY. "Their commitment never wavered, from early calls to late-night check-ins, they were true partners every step of the way. We're grateful to have had their guidance," added Dr. Lee Kaback, Vice President of OrthoNY. "They understood what makes OrthoNY unique and helped us protect and strengthen that as we look toward the future." "The OrthoNY leadership team engaged with Provident under the vision of developing a new regionally focused musculoskeletal platform with a partner. Zenyth Partners is a perfect match given their dedicated thesis in the MSK sector and experience developing other provider platforms in the Northeast region. We look forward to following the continued success of Evolve," noted Major. About OrthoNYOrthoNY is a leading orthopedic practice providing comprehensive musculoskeletal care, including surgical and non-surgical treatments, across multiple locations in Upstate New York. The Company is recognized for its expertise in joint replacement, sports medicine, spine care, pain management and more. With a strong reputation for clinical excellence and compassionate care, OrthoNY continues to be a top choice for orthopedic services in the region. For more information, visit About Zenyth PartnersZenyth Partners is an operationally focused investment firm focused exclusively on building leading healthcare companies. Zenyth partners with entrepreneurs, clinicians, and operators that share similar values, creating differentiated healthcare organizations that support patients, providers, payors, and the community at large. For more information, visit About Provident Healthcare PartnersProvident is a leading healthcare investment banking firm specializing in merger and acquisition advisory, strategic planning, and capital formation services for healthcare companies. The firm has a comprehensive knowledge of market sectors and specialties, including orthopedics. Provident also has unsurpassed experience and insight into the M&A process, which includes working with a multitude of investors such as private equity firms and strategic consolidators. For additional information, visit or follow Provident on LinkedIn. Contact: Provident Healthcare PartnersEric Major 617-226-4212 emajor@ View original content to download multimedia: SOURCE Provident Healthcare Partners LLC
Yahoo
2 hours ago
- Yahoo
Should You Take a Vitamin B12 Supplement?
Credit - Photo-Illustration by TIME (Source Images: eyenigelen/Getty Images, Sersol/Getty Images) Everyone needs vitamin B12: It helps the body produce red blood cells and maintain healthy brain function, along with so many other things. But are you getting enough of it? Here's what to know about vitamin B12 and whether you should consider upping your levels. A boon for brain health 'Vitamin B12 is important for brain health because it helps protect nerve cells in the brain, which support memory and thinking skills,' says Michelle Routhenstein, a preventive cardiology dietitian and certified diabetes educator in New York. It's water-soluble, so the body does not store it in large amounts, and daily intake is essential. The current federal recommendations are for adults to get 2.4 mcg of vitamin B12 per day. Great food sources of B12 include seafood like oysters, salmon and tuna, beef, and fortified products like nutritional yeast, plant-based milks, some breads and breakfast cereals, says Routhenstein. But some recent research suggests that some people may need even more than that. Vitamin B12 deficiencies can impact your brain function even when your intake levels are considered normal, says Dr. Ari J. Green, a professor at the University of California, San Francisco's department of ophthalmology. In a recent study, Green and his colleagues found that people with B12 levels that were technically normal but on the lower end of the range had impaired brain function. 'We could detect neurological impairment at levels currently considered 'normal,' independently of other factors like years of education," particularly in older people, says Dr. Alexandra Beaudry-Richard, a resident at McGill University and co-author of the study. 'To us, this should reinvigorate a conversation about how much B12 is needed for optimal neurological function.' Read More: Should You Take a Vitamin D Supplement? Other studies have found that people with Alzheimer's disease and mild cognitive impairment tend to have lower B12 levels—and supplementation with B12 can reduce the rate of brain atrophy. However, on the opposite end, the study showed signs of a possible detrimental effect on the brain when people had high B12 levels in their blood. 'This warrants further studies to evaluate what healthy B12 levels are on both ends of the spectrum,' says Dr. Ahmed Abdelhak, one of the study's authors and a clinical instructor in neurology at UCSF School of Medicine. Should you take a B12 supplement? You can (and should) get B12 from your diet, but some people may have a tough time getting adequate levels of the nutrient from food alone. Older adults are more likely to develop vitamin B12 deficiencies because the vitamin requires stomach acid to be absorbed, and stomach acid production starts to decline with age. Routhenstein recommends people look closer into their B12 status starting around age 50 or if they are at higher risk of a B12 deficiency. This category includes vegans and vegetarians, people taking specific medications that interfere with B12 absorption such as metformin or proton pump inhibitors, and those who have gastrointestinal disorders like Crohn's, celiac, or atrophic gastritis. You can get tested for a vitamin B12 deficiency at your annual physical. If you are deficient, your doctor might recommend supplementation. Read More: 7 Surprising Symptoms of Lyme Disease The UCSF study authors recommend checking levels starting at age 70, but you can get it checked on a standard blood test at any age through your primary care physician. Dr. Ralph Green, a professor of pathology and lab medicine at the University of California, Davis—and another author on that recent study—says that checking B12 may also be valuable for people who have unexplained symptoms that have been linked to B12 deficiency. For those with declining gastric function, he says taking supplements is likely the best way to promote absorption, and the level of supplementation a person should consume depends on whether their absorption is normal or not. Pregnant women, too, need higher B12 intake to support fetal brain development; if you're pregnant, consult with your ob-gyn about optimal B12 levels for you. What kind of B12 supplement is best? B12 in supplements and fortified foods can be more easily absorbed than from food, especially for older adults and those with absorption issues, says Routhenstein. If your doctor has advised you to take a B12 supplement, it's best to ask them to recommend specific dosages and brands. But Routhenstein recommends following these general guidelines when selecting a B12 supplement. Always look for those with methylcobalamin on the label, as this is the most bioavailable form of B12, meaning the body can absorb it the best. It's also the optimal form for heart and brain health and nerve function, she says. Sublingual (under the tongue) or liquid B12 is often touted for better absorption. This form of B12 does so 'by bypassing the digestive system and entering the bloodstream directly,' says Routhenstein. Of course, no supplement is a cure-all, and there are other ways to support brain health, including maintaining a healthy diet and exercise regimen. Activities that stimulate multiple brain areas simultaneously are excellent at promoting cognitive longevity, Beaudry-Richard says. Practicing a musical instrument, dancing, and studying a foreign language daily, for example, all recruit 'brain circuits responsible for vision, hearing, movement, emotions' and more. 'It's like a full-body workout for the brain,' she says. Contact us at letters@